Epidyne®-FRET for Nucleosome Remodeling Assays

Total Page:16

File Type:pdf, Size:1020Kb

Epidyne®-FRET for Nucleosome Remodeling Assays Nucleosome Remodeling Assay by EpiDyne®-FRET EpiDyne®-FRET allows unprecedented access to disease-relevant ATP-dependent chromatin remodeling complexes FIGURE 3 SMARCA 2 SMARCA 4 EpiDyne®-FRET nucleosomes (20 nM) were incubated with Figure 3A Figure 3B chromatin remodeling enzyme (Panel 3A, SMARCA2; panel 3B, SMARCA4) at the indicated concentration in 4.0 3.5 the presence of ATP (2 mM). 3.5 Upon ATP addition, reactions 3.0 were immediately read in 3.0 an Envision Multi-label plate 2.5 reader. Data are presented as 2.5 the mean of the Cy3-Cy5 ratio 2.0 (N=2). 2.0 1.5 Cy3/Cy5 Ratio Cy3/Cy5 1.5 Ratio Cy3/Cy5 1.0 1.0 0 1 2 3 4 5 6 7 8 9 10 0 10 20 30 40 Time, Min Time, Min nM Enzyme nM Enzyme 28 14 7 3.5 0.0 12.50 6.25 3.13 1.56 0 ORDERING INFO Chromatin Remodeling Substrate, Fluorescent Readout Enzymes EpiDyne®-FRET Nucleosome Remodeling Assay Substrate SMARCA2 Chromatin Remodeling Enzyme Catalog No. 16-4201 (Human BRM) Pack Size: 50 μg Catalog No. 15-1015 Pack Size: 100 remodeling rxns Chromatin Remodeling Substrates, Non-Fluorescent Readout SMARCA4 Chromatin Remodeling Enzyme (Human BRG1) ST601-GATC1 ST601-GATC1, 50-N-66, Biotinylated Catalog No. 15-1014 Cat. No. 16-4101 Cat. No.: 16-4114 Pack Size: 100 remodeling rxns Pack Size: 50 μg Pack Size: 50 μg ACF Chromatin Remodeling Enzyme Complex ST601-GATC1, Biotinylated ST601-GATC1,2, 50-N-66, Biotinylated Catalog No. 15-1013 Cat. No.: 16-4111 Cat. No.: 16-4115 Pack Size: 100 remodeling rxns Pack Size: 50 μg Pack Size: 50 μg Website: epicypher.com/epidyne-enzymes ST601-GATC1,2, Biotinylated ST601-GATC1,2,3, 50-N-66, Biotinylated Cat. No.: 16-4112 Cat. No.: 16-4116 Pack Size: 50 μg Pack Size: 50 μg EpiDyne® Chromatin Remodeling HTS Assay Services are available ST601-GATC1,2,3, Biotinylated Website: epicypher.com/epidyne Inquire at: [email protected] Cat. No.: 16-4113 Pack Size: 50 μg EpiDyne®-FRET , RTP, NC. All rights reserved. , RTP, ® For Nucleosome EpiCypher.com Remodeling Assays 855.374.2461 • [email protected] March, 2020 v.3.0 March, ©2020 EpiCypher Nucleosome Remodeling Assay by EpiDyne®-FRET Nucleosome Remodeling Assay by EpiDyne®-FRET EpiDyne®-FRET: a functionalized recombinant nucleosome-based assay Chromatin Remodeling Enzymes As Therapeutic Targets platform for chromatin remodeling studies Aberrant nucleosome organization can severely disrupt gene expression, DNA repair and cellular differentiation, and it also plays a major role in human disorders, including Chromatin remodeling, or the repositioning of nucleosomes, regulates DNA access and cancer, infammation, autoimmunity, schizophrenia, cardiovascular disease, and intellectual thus gene expression and genome repair. Many ATP-dependent remodeling enzyme disability. Remarkably, nearly 20% of all cancers contain mutations in subunits from the complexes are associated with human disease but are challenging study targets due to SWI/SNF family of ATP-dependent chromatin remodeling complexes. These enzyme the requirement for nucleosome-based substrates. EpiCypher® has addressed this need by complexes regulate local genome access by ‘pumping’ the DNA around histone octamers, developing the EpiDyne® platform of fully recombinant remodeling substrates to monitor thus ‘sliding’ nucleosomes. nucleosome repositioning along DNA using Fluorescence Resonance Energy Transfer (FRET) readout (Figure 1). SWI/SNF Remodeling Complex FIGURE 2 FIGURE 1 ® EpiDyne -FRET Bromodomain Schematic of SWI/SNF EpiDyne®-FRET Nucleosome remodeling complex. PBRM1* Remodeling Substrates PHF10 PHD finger Domain Yellow subunits denote consist of a Cy5-labeled DNA binding domain minimal core complex human histone octamer (H2A that recapitulates activity T120C-Cy5; shown as red SANT domain (histone tail binding) 685 nm SMARCD1 of full complex. section of octamer) wrapped SMARCB1* by 5’ Cy3-labeled DNA Nucleosome Remodeling ARID1A/B* (217bp; green ball) comprising Minimal SWI/SNF Core Complex a terminal nucleosome BCL7A-C SS18 positioning sequence (147bp Other possible subunits present Widom 601 adjacent to a SMARCA2/4* in SWI/SNF complexes TGGA-repeat region refractory BRD7* to nucleosome assembly. In its ACTL6A assembled starting state, Cy3- Cy5 FRET is at a maximum. FRET SMARCC1 SMARCC2 ACTB The activity of an ATP- SMARCE1* dependent remodeler (e.g. RSC or another SWI/SNF ATPase) is detected by a reduction in FRET signal H3K14ac as the Cy3-labeled DNA 5’ interacting end is moved away from the Cy5-labeled octamer. EpiDyne®-FRET is a one- step no-wash method 535 nm Recurrent somatic mutations in SWI/SNF subunits are observed in multiple cancers, immediately compatible with HTS applications. supporting a driver role in tumorigenesis. The mutated remodeling proteins are attractive 535 nm therapeutic targets, since further compromising their ATPase activity promotes cancer cell death but spares normal cells. TABLE 1 SUBUNIT CANCER Useful for List of cancers associated with various SWI/SNF ARID1A Ovarian, Hepatocellular, Bladder, Gastric, Endometrioid, Pancreatic, Colon, Lung, subunit mutations adapted Neuroblastoma, Burkitt Lymphoma • Inhibitor screening and development from Helming et al. Cancer ARID1B Melanoma, Neuroblastoma, Hepatocellular, Pancreatic, Liver Cell 26, 309-317 (2014). Asterisks in Figure 2 indicate • Structure-Activity Relationship assays PBRM1 Renal cell carcinoma, Breast, Gastric, Pancreatic associated cancers in Table 1. ARID2 Melanoma, Hepatocellular, Pancreatic • Biochemical profiling of ATPase family proteins SMARCA2 Lung, Colon, Breast SMARCA4 Lung, Medulloblastoma, Burkitt Lymphoma, SCCOHT SMARCB1 Rhaboid tumor, Familial Schwannomatosis SMARCE1 Spinal meningitis BRD7 Breast Nucleosome Remodeling Assay by EpiDyne®-FRET Nucleosome Remodeling Assay by EpiDyne®-FRET EpiDyne®-FRET: a functionalized recombinant nucleosome-based assay Chromatin Remodeling Enzymes As Therapeutic Targets platform for chromatin remodeling studies Aberrant nucleosome organization can severely disrupt gene expression, DNA repair and cellular differentiation, and it also plays a major role in human disorders, including Chromatin remodeling, or the repositioning of nucleosomes, regulates DNA access and cancer, infammation, autoimmunity, schizophrenia, cardiovascular disease, and intellectual thus gene expression and genome repair. Many ATP-dependent remodeling enzyme disability. Remarkably, nearly 20% of all cancers contain mutations in subunits from the complexes are associated with human disease but are challenging study targets due to SWI/SNF family of ATP-dependent chromatin remodeling complexes. These enzyme the requirement for nucleosome-based substrates. EpiCypher® has addressed this need by complexes regulate local genome access by ‘pumping’ the DNA around histone octamers, developing the EpiDyne® platform of fully recombinant remodeling substrates to monitor thus ‘sliding’ nucleosomes. nucleosome repositioning along DNA using Fluorescence Resonance Energy Transfer (FRET) readout (Figure 1). SWI/SNF Remodeling Complex FIGURE 2 FIGURE 1 ® EpiDyne -FRET Bromodomain Schematic of SWI/SNF EpiDyne®-FRET Nucleosome remodeling complex. PBRM1* Remodeling Substrates PHF10 PHD finger Domain Yellow subunits denote consist of a Cy5-labeled DNA binding domain minimal core complex human histone octamer (H2A that recapitulates activity T120C-Cy5; shown as red SANT domain (histone tail binding) 685 nm SMARCD1 of full complex. section of octamer) wrapped SMARCB1* by 5’ Cy3-labeled DNA Nucleosome Remodeling ARID1A/B* (217bp; green ball) comprising Minimal SWI/SNF Core Complex a terminal nucleosome BCL7A-C SS18 positioning sequence (147bp Other possible subunits present Widom 601 adjacent to a SMARCA2/4* in SWI/SNF complexes TGGA-repeat region refractory BRD7* to nucleosome assembly. In its ACTL6A assembled starting state, Cy3- Cy5 FRET is at a maximum. FRET SMARCC1 SMARCC2 ACTB The activity of an ATP- SMARCE1* dependent remodeler (e.g. RSC or another SWI/SNF ATPase) is detected by a reduction in FRET signal H3K14ac as the Cy3-labeled DNA 5’ interacting end is moved away from the Cy5-labeled octamer. EpiDyne®-FRET is a one- step no-wash method 535 nm Recurrent somatic mutations in SWI/SNF subunits are observed in multiple cancers, immediately compatible with HTS applications. supporting a driver role in tumorigenesis. The mutated remodeling proteins are attractive 535 nm therapeutic targets, since further compromising their ATPase activity promotes cancer cell death but spares normal cells. TABLE 1 SUBUNIT CANCER Useful for List of cancers associated with various SWI/SNF ARID1A Ovarian, Hepatocellular, Bladder, Gastric, Endometrioid, Pancreatic, Colon, Lung, subunit mutations adapted Neuroblastoma, Burkitt Lymphoma • Inhibitor screening and development from Helming et al. Cancer ARID1B Melanoma, Neuroblastoma, Hepatocellular, Pancreatic, Liver Cell 26, 309-317 (2014). Asterisks in Figure 2 indicate • Structure-Activity Relationship assays PBRM1 Renal cell carcinoma, Breast, Gastric, Pancreatic associated cancers in Table 1. ARID2 Melanoma, Hepatocellular, Pancreatic • Biochemical profiling of ATPase family proteins SMARCA2 Lung, Colon, Breast SMARCA4 Lung, Medulloblastoma, Burkitt Lymphoma, SCCOHT SMARCB1 Rhaboid tumor, Familial Schwannomatosis SMARCE1 Spinal meningitis BRD7 Breast Nucleosome Remodeling Assay by EpiDyne®-FRET EpiDyne®-FRET allows unprecedented access to disease-relevant ATP-dependent chromatin remodeling complexes FIGURE 3 SMARCA 2 SMARCA 4 EpiDyne®-FRET nucleosomes (20 nM) were incubated with Figure 3A Figure 3B chromatin remodeling enzyme (Panel
Recommended publications
  • Statistical Analysis of the Genomic Distribution and Correlation of Regulatory Elements in the ENCODE Regions
    Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Statistical analysis of the genomic distribution and correlation of regulatory elements in the ENCODE regions Zhengdong D. Zhang,1 Alberto Paccanaro,2 Yutao Fu,3 Sherman Weissman,5 Zhiping Weng,3,4 Joseph Chang,6 Michael Snyder,7 and Mark B. Gerstein1,8,9 1Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA; 2Department of Computer Science Royal Holloway, University of London, Egham Hill, TW20 0EX, United Kingdom; 3Bioinformatics Program, Boston University, Boston, Massachusetts 02215, USA; 4Biomedical Engineering Department, Boston University, Boston, Massachusetts 02215, USA; 5Department of Genetics, Yale University, New Haven, Connecticut 06510, USA; 6Department of Statistics, Yale University, New Haven, Connecticut 06520, USA; 7Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520, USA; 8Program in Computational Biology and Bioinformatics Yale University, New Haven, Connecticut 06520, USA The comprehensive inventory of functional elements in 44 human genomic regions carried out by the ENCODE Project Consortium enables for the first time a global analysis of the genomic distribution of transcriptional regulatory elements. In this study we developed an intuitive and yet powerful approach to analyze the distribution of regulatory elements found in many different ChIP–chip experiments on a 10∼100-kb scale. First, we focus on the overall chromosomal distribution of regulatory elements in the ENCODE regions and show that it is highly nonuniform. We demonstrate, in fact, that regulatory elements are associated with the location of known genes. Further examination on a local, single-gene scale shows an enrichment of regulatory elements near both transcription start and end sites.
    [Show full text]
  • Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma
    Open Access Case Report DOI: 10.7759/cureus.13082 Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma Manpreet Singh 1 , Harkirat Singh 1 , Benjamin Hambro 1 , Jasleen Kaur 1 , Ravi Rao 2 1. Internal Medicine, St Agnes Medical Center, Fresno, USA 2. Hematology and Oncology, St Agnes Medical Center, Fresno, USA Corresponding author: Manpreet Singh, [email protected] Abstract Members of the SWItch/sucrose nonfermentable (SWI-SNF) family, including SWI/SNF related, matrix- associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SWI/SNF related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily B member 1 (SMARCB1)/integrase interactor 1 (INI-1) are known tumor suppressor genes. Interactions between SMARCB1/INI-1 and key protein components in various cellular pathways are related to tumor progression and proliferation. SMARCB1/INI-1 protein was undetectable in rhabdoid tumor cells, whereas non-tumorous cells express the SMARCB1/INI-1 genes. Germline and sporadic mutations of several genes encoding for proteins in this complex are known to cause a spectrum of cancers, usually with sarcomatoid features which include a very aggressive renal medullary carcinoma. We report a case of a 29-year-old male who presented with SMARCA4 deficient renal tumor with a very aggressive clinical behavior which ultimately led to his death. Categories: Nephrology, Oncology Keywords: renal medullary carcinoma, ini-1, renal cell carcinoma, swi/snf, smarcb1, integrase interactor 1 Introduction Renal medullary carcinoma is a rare and very aggressive malignancy affecting young adults with rare cases in patients with sickle cell disease or trait [1]. The tumor arises predominantly in the renal medulla and exhibits a variety of growth patterns including reticular, solid, tubular, trabecular, cribriform, sarcomatoid, and micropapillary [1].
    [Show full text]
  • Bioinformatics Applications Through Visualization of Variations on Protein
    1 Bioinformatics applications through visualization of variations on protein structures, comparative functional genomics, and comparative modeling for protein structure studies A dissertation presented by Alper Uzun to The Department of Biology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Biology Northeastern University Boston, Massachusetts July 2009 2 ©2009 Alper Uzun ALL RIGHTS RESERVED 3 Bioinformatics applications through visualization of variations on protein structures, comparative functional genomics, and comparative modeling for protein structure studies by Alper Uzun ABSTRACT OF DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology in the Graduate School of Arts and Sciences of Northeastern University, July, 2009 4 Abstract The three-dimensional structure of a protein provides important information for understanding and answering many biological questions in molecular detail. The rapidly growing number of sequenced genes and related genomic information is intensively accumulating in the biological databases. It is significantly important to combine biological data and developing bioinformatics tools while information of protein sequences, structures and DNA sequences are exponentially growing. On the other hand, especially the number of known protein sequences is much larger than the number of experimentally solved protein structures. However the experimental methods cannot always be applied or protein structures
    [Show full text]
  • Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
    Published OnlineFirst May 4, 2017; DOI: 10.1158/2159-8290.CD-17-0292 RESEARCH ARTICLE Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade Yi-Feng Gu1,2, Shannon Cohn1,2, Alana Christie2, Tiffani McKenzie2,3, Nicholas Wolff1,2, Quyen N. Do4, Ananth J. Madhuranthakam4, Ivan Pedrosa2,4, Tao Wang2,5, Anwesha Dey6, Meinrad Busslinger7, Xian-Jin Xie2,8, Robert E. Hammer9, Renée M. McKay1,2, Payal Kapur2,3, and James Brugarolas1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 26, 2021. © 2017 American Association for Cancer Research. 17-CD-17-0292_p900-917.indd 900 7/20/17 10:05 AM Published OnlineFirst May 4, 2017; DOI: 10.1158/2159-8290.CD-17-0292 ABSTRACT Clear cell renal cell carcinoma (ccRCC) is characterized by BAP1 and PBRM1 muta- tions, which are associated with tumors of different grade and prognosis. However, whether BAP1 and PBRM1 loss causes ccRCC and determines tumor grade is unclear. We conditionally targeted Bap1 and Pbrm1 (with Vhl ) in the mouse using several Cre drivers. Sglt2 and Villin proximal convoluted tubule drivers failed to cause tumorigenesis, challenging the conventional notion of ccRCC origins. In contrast, targeting with PAX8, a transcription factor frequently overexpressed in ccRCC, led to ccRCC of different grades. Bap1 -defi cient tumors were of high grade and showed greater mTORC1 activation than Pbrm1 -defi cient tumors, which exhibited longer latency. Disrupting one allele of the mTORC1 negative regulator, Tsc1 , in Pbrm1 -defi cient kidneys triggered higher grade ccRCC. This study establishes Bap1 and Pbrm1 as lineage-specifi c drivers of ccRCC and histologic grade, implicates mTORC1 as a tumor grade rheostat, and suggests that ccRCCs arise from Bowman capsule cells.
    [Show full text]
  • C/EBP Creates Elite Cells for Ipsc Reprogramming by Upregulating
    ARTICLES C/EBPα creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4 Bruno Di Stefano1,2,8,9,10, Samuel Collombet3,8, Janus Schou Jakobsen4,5,6,8, Michael Wierer7, Jose Luis Sardina1,2, Andreas Lackner1,2,9, Ralph Stadhouders1,2, Carolina Segura-Morales1,2, Mirko Francesconi1,2, Francesco Limone1,2, Matthias Mann7, Bo Porse4,5,6, Denis Thieffry3 and Thomas Graf1,2,10 Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) is typically inefficient and has been explained by elite-cell and stochastic models. We recently reported that B cells exposed to a pulse of C/EBPα (Bα0 cells) behave as elite cells, in that they can be rapidly and efficiently reprogrammed into iPSCs by the Yamanaka factors OSKM. Here we show that C/EBPα post-transcriptionally increases the abundance of several hundred proteins, including Lsd1, Hdac1, Brd4, Med1 and Cdk9, components of chromatin-modifying complexes present at super-enhancers. Lsd1 was found to be required for B cell gene silencing and Brd4 for the activation of the pluripotency program. C/EBPα also promotes chromatin accessibility in pluripotent cells and upregulates Klf4 by binding to two haematopoietic enhancers. Bα0 cells share many properties with granulocyte/macrophage progenitors, naturally occurring elite cells that are obligate targets for leukaemic transformation, whose formation strictly requires C/EBPα. The ability to reprogram somatic into pluripotent cells has revolu- complex process, where multiple players synergistically establish new tionized stem cell research with major implications for almost all transcriptional networks and remove epigenetic barriers14. Among the fields of modern biology.
    [Show full text]
  • Sox2-RNA Mechanisms of Chromosome Topological Control in Developing Forebrain
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.22.307215; this version posted September 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Sox2-RNA mechanisms of chromosome topological control in developing forebrain Ivelisse Cajigas1, Abhijit Chakraborty2, Madison Lynam1, Kelsey R Swyter1, Monique Bastidas1, Linden Collens1, Hao Luo1, Ferhat Ay2,3, Jhumku D. Kohtz1,4 1Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Department of Human Molecular Genetics, Stanley Manne Children's Research Institute 2430 N Halsted, Chicago, IL 60614 2Centers for Autoimmunity and Cancer Immunotherapy, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA, 92037, USA 3School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA 4To whom correspondence should be addressed: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.22.307215; this version posted September 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Precise regulation of gene expression networks requires the selective targeting of DNA enhancers. The Evf2 long non-coding RNA regulates Dlx5/6 ultraconserved enhancer(UCE) interactions with long-range target genes, controlling gene expression over a 27Mb region in mouse developing forebrain. Here, we show that Evf2 long range gene repression occurs through multi-step mechanisms involving the transcription factor Sox2, a component of the Evf2 ribonucleoprotein complex (RNP).
    [Show full text]
  • Increased ACTL6A Occupancy Within Mswi/SNF Chromatin Remodelers
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.435873; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Increased ACTL6A Occupancy Within mSWI/SNF Chromatin Remodelers Drives Human Squamous Cell Carcinoma Chiung-Ying Chang1,2,7, Zohar Shipony3,7, Ann Kuo1,2, Kyle M. Loh4,5, William J. Greenleaf3,6, Gerald R. Crabtree1,2,5* 1Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA. 4Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 5Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 6Department of Applied Physics, Stanford University, Stanford, California 94305, USA. 7These authors contributed equally. *Corresponding author: Gerald R. Crabtree, [email protected] Summary Mammalian SWI/SNF (BAF) chromatin remodelers play dosage-sensitive roles in many human malignancies and neurologic disorders. The gene encoding the BAF subunit, ACTL6A, is amplified at an early stage in the development of squamous cell carcinomas (SCCs), but its oncogenic role remains unclear. Here we demonstrate that ACTL6A overexpression leads to its stoichiometric assembly into BAF complexes and drives its interaction and engagement with specific regulatory regions in the genome. In normal epithelial cells, ACTL6A was sub-stoichiometric to other BAF subunits. However, increased ACTL6A levels by ectopic expression or in SCC cells led to near-saturation of ACTL6A within BAF complexes.
    [Show full text]
  • Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer
    diagnostics Article Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer Kung-Chen Ho 1, Jie-Jen Lee 1, Chi-Hsin Lin 2,3, Ching-Hsiang Leung 4 and Shih-Ping Cheng 1,5,* 1 Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, Taiwan; [email protected] (K.-C.H.); [email protected] (J.-J.L.) 2 Department of Medical Research, MacKay Memorial Hospital, Taipei 104215, Taiwan; [email protected] 3 Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan City 320314, Taiwan 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, Taiwan; [email protected] 5 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan * Correspondence: [email protected]; Tel.: +886-2-2543-3535 Received: 19 April 2020; Accepted: 2 May 2020; Published: 5 May 2020 Abstract: Alterations in the switching defective/sucrose non-fermenting (SWI/SNF) chromatin-remodeling complex are enriched in advanced thyroid cancer. Integrase interactor 1 (INI1), encoded by the SMARCB1 gene on the long arm of chromosome 22, is one of the core subunits of the SWI/SNF complex. INI1 immunohistochemistry is frequently used for the diagnosis of malignant rhabdoid neoplasms. In the present study, we found normal and benign thyroid tissues generally had diffusely intense nuclear immunostaining. Loss of INI1 immunohistochemical expression was observed in 8% of papillary thyroid cancer and 30% of follicular thyroid cancer. Furthermore, loss of INI1 expression was associated with extrathyroidal extension (p < 0.001) and lymph node metastasis (p = 0.038).
    [Show full text]
  • 1 Canonical BAF Complex in Regulatory T Cells 2 3 Chin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.26.964981; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A genome-wide CRISPR screen reveals a role for the BRD9-containing non- 2 canonical BAF complex in regulatory T cells 3 4 Chin-San Loo1,3,#, Jovylyn Gatchalian2,#, Yuqiong Liang1, Mathias Leblanc1, Mingjun 5 Xie1, Josephine Ho2, Bhargav Venkatraghavan1, Diana C. Hargreaves2*, and Ye 6 Zheng1* 7 8 1. NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for 9 Biological Studies 10 2. Molecular and Cellular Biology Laboratory, Salk Institute for Biological Studies 11 3. Division of Biological Sciences, University of California, San Diego 12 # Co-first authors 13 * Co-corresponding authors 14 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.26.964981; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 15 Summary 16 Regulatory T cells (Tregs) play a pivotal role in suppressing auto-reactive T cells 17 and maintaining immune homeostasis. Treg development and function are 18 dependent on the transcription factor Foxp3. Here we performed a genome-wide 19 CRISPR/Cas9 knockout screen to identify the regulators of Foxp3 in mouse 20 primary Tregs. The results showed that Foxp3 regulators are highly enriched in 21 genes encoding SWI/SNF and SAGA complex subunits. Among the three 22 SWI/SNF-related complexes, the non-canonical or ncBAF (also called GBAF or 23 BRD9-containing BAF) complex promoted the expression of Foxp3, whereas the 24 PBAF complex repressed its expression.
    [Show full text]
  • Swi/Snf Chromatin Remodeling/Tumor Suppressor Complex Establishes Nucleosome Occupancy at Target Promoters
    Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters Michael Y. Tolstorukova,b,1,2, Courtney G. Sansamc,d,e,1, Ping Luc,d,e,1, Edward C. Koellhofferc,d,e, Katherine C. Helmingc,d,e, Burak H. Alvera, Erik J. Tillmanc,d,e, Julia A. Evansc,d,e, Boris G. Wilsonc,d,e, Peter J. Parka,b,3, and Charles W. M. Robertsc,d,e,3 aCenter for Biomedical Informatics, Harvard Medical School, Boston, MA 02115; bDivision of Genetics, Brigham and Women’s Hospital, Boston, MA 02115; cDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; dDivision of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02115; and eDepartment of Pediatrics, Harvard Medical School, Boston, MA 02115 Edited by Mark Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, and approved May 2, 2013 (received for review February 6, 2013) Precise nucleosome-positioning patterns at promoters are thought Brg1 haploinsufficient mice are tumor prone, establishing these to be crucial for faithful transcriptional regulation. However, the subunits of the complex as bona fide tumor suppressors (1, 12–17). mechanisms by which these patterns are established, are dynam- It is noteworthy that recent exome sequencing of 35 human SNF5- ically maintained, and subsequently contribute to transcriptional deficient rhabdoid tumors identified a remarkably low rate of control are poorly understood. The switch/sucrose non-fermentable mutations, with loss of SNF5 being essentially the sole recurrent event (18). Indeed, in two of the cancers, there were no other chromatin remodeling complex, also known as the Brg1 associated fi factors complex, is a master developmental regulator and tumor identi ed mutations.
    [Show full text]
  • Renal Medullary Carcinomas Depend Upon SMARCB1 Loss And
    RESEARCH ARTICLE Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition Andrew L Hong1,2,3, Yuen-Yi Tseng3, Jeremiah A Wala3, Won-Jun Kim2, Bryan D Kynnap2, Mihir B Doshi3, Guillaume Kugener3, Gabriel J Sandoval2,3, Thomas P Howard2, Ji Li2, Xiaoping Yang3, Michelle Tillgren2, Mahmhoud Ghandi3, Abeer Sayeed3, Rebecca Deasy3, Abigail Ward1,2, Brian McSteen4, Katherine M Labella2, Paula Keskula3, Adam Tracy3, Cora Connor5, Catherine M Clinton1,2, Alanna J Church1, Brian D Crompton1,2,3, Katherine A Janeway1,2, Barbara Van Hare4, David Sandak4, Ole Gjoerup2, Pratiti Bandopadhayay1,2,3, Paul A Clemons3, Stuart L Schreiber3, David E Root3, Prafulla C Gokhale2, Susan N Chi1,2, Elizabeth A Mullen1,2, Charles WM Roberts6, Cigall Kadoch2,3, Rameen Beroukhim2,3,7, Keith L Ligon2,3,7, Jesse S Boehm3, William C Hahn2,3,7* 1Boston Children’s Hospital, Boston, United States; 2Dana-Farber Cancer Institute, Boston, United States; 3Broad Institute of Harvard and MIT, Cambridge, United States; 4Rare Cancer Research Foundation, Durham, United States; 5RMC Support, North Charleston, United States; 6St. Jude Children’s Research Hospital, Memphis, United States; 7Brigham and Women’s Hospital, Boston, United States Abstract Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele. Biochemical and functional characterization of these models revealed that RMC requires the loss of SMARCB1 for survival.
    [Show full text]
  • Identification of a Core Member of the SWI/SNF Complex, BAF155/SMARCC1, As a Human Tumor Suppressor Gene
    RESEARCH PAPER Epigenetics 6:12, 1444-1453; December 2011; © 2011 Landes Bioscience Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene Jessica DelBove,1,6 Gary Rosson,2,7 Matthew Strobeck,3 Jianguang Chen,4 Trevor K. Archer,4 Weidong Wang,5 Erik S. Knudsen3 and Bernard E. Weissman1,2,* 1Department of Pathology and Laboratory Medicine; 2University of North Carolina-Lineberger Comprehensive Cancer Center; 7Department of Genetics; University of North Carolina; Chapel Hill, NC USA; 3Department of Cancer Biology and the Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; 4Chromatin and Gene Expression Section; Laboratory of Molecular Carcinogenesis; National Institute of Environmental Health Sciences; National Institutes of Health; Research Triangle Park, NC USA; 5Laboratory of Genetics; National Institute on Aging; National Institutes of Health; Baltimore, MD USA; 6Department of Hematology; University of Utah School of Medicine; Salt Lake City, UT USA Key words: SWI/SNF, BAF155, SMARCC1, tumor suppressor gene, cancer epigenetics Recent studies have established that two core members of the SWI/SNF chromatin remodeling complex, BRG1 and SNF5/ INI1, possess tumor-suppressor activity in human and mouse cancers. While the third core member, BAF155, has been implicated by several studies as having a potential role in tumor development, direct evidence for its tumor suppressor activity has remained lacking. Therefore, we screened for BAF155 deficiency in a large number of human tumor cell lines. We identified two cell lines, the SNUC2B colon carcinoma and the SKOV3 ovarian carcinoma, displaying a complete loss of protein expression while maintaining normal levels of mRNA expression.
    [Show full text]